EAST BRUNSWICK, N.J., April 30 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the first quarter 2010 following the close of the market on Wednesday May 5, 2010.
Paul Hamelin, R.Ph., President and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 10:00 a.m. Eastern Time on May 6, 2010 to discuss these results and to answer questions.
To participate by telephone, please dial 888-357-3694 (Domestic) or 973-890-8276 (International). The conference identification number is 72128037. The live and archived webcast can be accessed on the investor relations section of the Savient website at www.savient.com. Please log on to Savient's website 15 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.
A telephone replay will be available from 1:00 p.m. Eastern Time on May 6, 2010 through 11:59 p.m. Eastern Time on May 20, 2010 by dialing 800-642-1687 (Domestic) or 706-645-9291 (International) and entering conference ID number 72128037.
ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA, formerly referred to as Puricase®, from Duke University and Mountain View Pharmaceuticals, Inc. Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc.
|SOURCE Savient Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved